The treatment of low-risk prostate cancer is a common clinical dilemma between standard curative whole gland therapy (and its associated quality of life diminishing side effects) and active surveillance (and its low, but real, risk of progression).
The goal of focal therapy in low-risk prostate cancer is to achieve the best balance between cancer control and maintenance of quality of life. Magnetic resonance-guided focused ultrasound (MRgFUS) surgery is a non-invasive thermal ablation method that integrates magnetic resonance imaging for target identification, treatment planning and closed-loop control of thermal deposition and focused ultrasound for thermal ablation of the tumour target. This novel transrectal system allows for tumour localization, targeting and monitoring of tumour target ablation in real time, while simultaneously preserving adjacent normal tissue thereby minimizing the side effects of standard curative surgical or radiation therapy. We report the first North American clinical experience of treatment of localized prostate cancer with focal MR-guided transrectal focused ultrasound (clinicaltrial.gov identifier NCT01226576).
Written by:
Lindner U, Ghai S, Spensieri P, Hlasny E, Van Der Kwast TH, McCluskey SA, Haider MA, Kucharczyk W, Trachtenberg J. Are you the author?
Division of Urology, Department of Surgical Oncology, University Health Network, and Department of Surgery, University of Toronto, Toronto, ON.
Reference: Can Urol Assoc J. 2012 Dec;6(6):E283-6.
doi: 10.5489/cuaj.12218
PubMed Abstract
PMID: 23283106
UroToday.com Prostate Cancer Section
